What is CoMind?
CoMind Technologies Limited operates at the intersection of advanced photonics and clinical neurotechnology. The company is dedicated to redefining how medical professionals measure and treat brain functions, aiming to enhance patient outcomes across the entire healthcare continuum. Their core innovation centers on a non-invasive, bedside measurement platform that provides clinicians with real-time access to critical neurophysiological signals. By simplifying the diagnostic process, CoMind addresses a significant unmet need in the neuro-monitoring market, moving away from cumbersome, invasive procedures toward streamlined, data-driven clinical practices. This technological shift is designed to empower healthcare providers with actionable insights, ultimately improving the standard of care for patients requiring neurological assessment.
How much funding has CoMind raised?
CoMind has raised a total of $59M across 1 funding round:
Other Financing Round
$59M
Other Financing Round (2025): $59M with participation from Angelini Ventures, Octopus Ventures, Latitude, LocalGlobe, and Plural VC
Key Investors in CoMind
Angelini Ventures
Angelini Ventures is a venture capital firm that invests in BioTech and HealthTech companies, focusing on transforming healthcare through technology.
Octopus Ventures
Octopus Ventures is a founder-focused venture capital firm backing mission-driven companies across software, health, and financial technology.
Plural VC
Plural VC is a venture community composed of operators and investors focused on supporting early-stage companies with both capital and intellectual resources.
What's next for CoMind?
With the infusion of this major strategic investment, CoMind is poised to transition from its current development phase toward broader clinical validation and commercial scaling. The company's roadmap likely includes the refinement of its photonics hardware to ensure seamless integration into existing hospital workflows and the pursuit of regulatory milestones necessary for widespread adoption. As the firm scales, it will focus on building out its intellectual property portfolio and establishing strategic partnerships with major healthcare systems. The objective is to solidify its position as a leader in the neurotechnology space, ensuring that its non-invasive diagnostic tools become a staple in intensive care and neurological units globally. Continued focus on clinical efficacy and user-centric design will be paramount as the company navigates the complexities of the medical device market.
See full CoMind company page
